Drug intelligence / Profile preview

PRX105

Development stage: Preclinical
Lead developer: Prazer Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral

Overview

PRX105 is a preclinical-stage degrader-antibody conjugate (DAC) payload being developed by Prazer Therapeutics. It is designed to enable targeted protein degradation (TPD) of Bromodomain-containing protein 4 (BRD4) and an additional undisclosed target. Utilizing Prazer's expertise in TPD, PRX105 is intended to be conjugated to antibodies to selectively deliver the degrader payload to target cells, offering a potential therapeutic approach for undisclosed indications, likely in oncology or other diseases where BRD4 is implicated.

Targets

BRD2 (Bromodomain-containing protein 2)BRD4 (Bromodomain-containing protein 4)BRD3 (Bromodomain-containing protein 3)BRDT (Bromodomain testis-specific protein)

Beyond the preview

Go deeper on PRX105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX105.

Explore the full profile